Evaluation of Drug-Drug Interaction Potential of PRAX-628 in a Phase 1, Open-Label, Multiple-Part Trial in Healthy Participants with Epilepsy

The primary objective of this study is to evaluate the **drug-drug interaction** potential of PRAX-628 in healthy participants. Understanding these interactions is clinically relevant as it helps to ensure the safe and effective use of PRAX-628, particularly in patients with **epilepsy**, where polypharmacy is common. No secondary objectives are provided for this study.

The clinical trial involves participants diagnosed with **epilepsy**. The study population includes both male and female subjects, with an age range categorized as 3, which typically corresponds to adults. The general health status of participants is not specified, and the sponsor has not provided information regarding the total number of participants. The trial population was selected without targeting any vulnerable groups. Lifestyle considerations such as diet, physical activity, or habits have not been detailed. Key inclusion or exclusion criteria have not been disclosed by the sponsor.

The clinical trial is designed as a **Phase 1**, open-label, multiple-part study to evaluate the drug-drug interaction potential of PRAX-628 in healthy participants. The trial is focused on understanding the interactions of PRAX-628, a compound under investigation, in the context of **epilepsy**. The trial is scheduled to commence recruitment on August 13, 2024, and is expected to conclude by December 17, 2024. The study does not involve a randomized or double-blind design, as it is primarily exploratory in nature.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria will be assessed. This visit will determine the participant's suitability for the trial based on predefined inclusion and exclusion criteria. Following successful screening, participants will proceed to the treatment phase, which will include multiple follow-up visits to monitor drug interactions and collect relevant data. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to ensure participant safety and gather comprehensive data for analysis.

The expected duration of participant involvement will vary depending on the specific part of the trial they are enrolled in, but it is anticipated to span several weeks. Conditions that may lead to early termination from the study include adverse reactions to the investigational product, non-compliance with study protocols, or withdrawal of consent by the participant. The trial's design and procedures are structured to ensure the collection of high-quality data while maintaining participant safety and adherence to ethical standards.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on August 13, 2024, with an estimated completion date of December 17, 2024. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on evaluating the treatment's effectiveness in a larger patient population. The trial's design will likely include validated scales, laboratory tests, or patient-reported outcomes to measure efficacy, consistent with standard practices in clinical research. However, specific tools or instruments for efficacy assessments are not specified in the provided information.